Drug intelligence / Profile preview

MITI-101

Development stage: Preclinical
Lead developer: MindImmune Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

MITI-101 is a monoclonal antibody developed by Mindimmune Therapeutics for the treatment of neurodegenerative diseases, with a primary focus on Alzheimer’s disease. The drug is designed to intercept the immune response in neuroinflammatory conditions by neutralizing CD11c in the bloodstream, thereby preventing the recruitment of neuro-inflammatory immune cells into the brain. This mechanism aims to halt or slow down disease progression associated with harmful neuroinflammation. As of June 2025, MITI-101 remains in preclinical development and has not yet entered human clinical trials[1][3][7].

Targets

ITGAX (Integrin alpha-X)

Beyond the preview

Go deeper on MITI-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MITI-101.

Explore the full profile